Death Reported In Phase II Trial For Astellas/FibroGen’s Oral EPO Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Announcement comes just ahead of an FDA advisory committee meeting to discuss EPO products.
You may also be interested in...
AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas
The British pharma continues to build its cardiovascular and metabolic pipeline to slow its dive off the patent cliff; in FibroGen’s FG-4592, it sees a potential strong seller in regions where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen
FDA approves protocols proposed by FibroGen to resume Phase II trials of FG-2216 and FG-4592.
FDA Lifts Clinical Holds On Anemia Compounds Under Development By Astellas/FibroGen
FDA approves protocols proposed by FibroGen to resume Phase II trials of FG-2216 and FG-4592.